Skip to Content

Bristol-Myers, Pharmasset Plan Hepatitis C Study

From Associated Press (January 10, 2011)


NEW YORK -- Bristol-Myers Squibb Co. and Pharmasset Inc. said Monday they will run a clinical trial testing the combination of two hepatitis C drugs, one developed by each company.

Pharmasset’s drug is designated PSI-7977, and the Bristol-Myers Squibb drug is designated BMS-790052. Both drugs are in midstage clinical testing.

The trial will start in the first half of this year, and it will be designed to determine if patients who take the drug cocktail have undetectable levels of the hepatitis C virus after 24 weeks. The companies said they will focus on patients who have not previously been treated for the virus, and will study patients with a variety of types of hepatitis C. They will test the drugs in combination with ribavirin, a common hepatitis C therapy, as well as without ribavirin.

Shares of Bristol-Myers Squibb, based in New York, lost a penny to $25.79 in morning trading. Pharmasset, based in Princeton, N.J., was down $1.18 at $44.78.



Posted: January 2011